SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Goldman Sachs, ANZ Cut Oil Forecasts Amid U.S.-Iran Ceasefire Hopes 
Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
- Credit Suisse 25th Annual Healthcare Conference on November 7 in Scottsdale, Arizona
- Jefferies 2016 London Healthcare Conference on November 16 in London
- Citi 2016 Global Healthcare Conference on December 8 in New York City
SAN RAFAEL, Calif., Nov. 03, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer, will participate in the Credit Suisse 25th Annual Healthcare Conference on November 7, 2016 at 10:00am MT/12:00pm ET, in Scottsdale, Arizona. Management will also participate in the Jefferies 2016 London Healthcare Conference on November 16, 2016, in London and the Citi 2016 Global Healthcare Conference on December 8, 2016 at 8:45am ET, in New York City. Webcasts will be available for the Credit Suisse and Citi conferences. To access the live webcasts, please visit the investor section of the BioMarin website, www.BMRN.com. A replay will also be archived on the site for at least one week following the event.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for people with serious and life-threatening rare disorders. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates.
For additional information, please visit www.BMRN.com. Information on BioMarin's website is not incorporated by reference into this press release.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
